Comparative Pharmacology
Head-to-head clinical analysis: ESOMEPRAZOLE MAGNESIUM versus PRILOSEC OTC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESOMEPRAZOLE MAGNESIUM versus PRILOSEC OTC.
ESOMEPRAZOLE MAGNESIUM vs PRILOSEC OTC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase at the secretory surface of gastric parietal cells.
Proton pump inhibitor that irreversibly inhibits the H+/K+ ATPase enzyme (proton pump) in gastric parietal cells, suppressing gastric acid secretion.
20-40 mg orally once daily; for erosive esophagitis, 40 mg once daily for 4-8 weeks. IV: 20-40 mg once daily over 10-30 minutes.
20 mg orally once daily for 14 days for frequent heartburn; may repeat 14-day course every 4 months.
None Documented
None Documented
Terminal elimination half-life is approximately 1–1.5 hours in healthy individuals, but may be prolonged to 2–3 hours in poor metabolizers (CYP2C19) or patients with hepatic impairment. The effect on gastric acid secretion persists for 24 hours due to irreversible binding to proton pumps.
Approximately 0.5–1 hour in healthy subjects; longer (up to 3 hours) in slow metabolizers or hepatic impairment. Clinically, the duration of acid suppression exceeds the half-life due to accumulation in parietal cell canaliculi.
Approximately 80% of a dose is excreted as metabolites in urine, with the remainder (about 20%) eliminated in feces via biliary excretion. Less than 1% is excreted unchanged in urine.
Primarily hepatic metabolism; about 80% of metabolites are excreted in urine, and the remainder in feces via bile. Less than 1% of unchanged drug is excreted in urine.
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor